Equine C-Peptide antibody and antigen (recombinant protein)

Diagnostic anti-Equine C-Peptide antibodies pairs and antigen for animal health (animal Equine/Horse type 1 diabetes mellitus) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine disease testing products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-EQU-C-Peptide-Ag01Equine C-Peptide$3090.00
GMP-EQU-C-Peptide-Ab01Anti-Equine C-Peptide mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-C-Peptide-Ab02Anti-Equine C-Peptide mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-C-Peptide-Ab03Anti-Equine C-Peptide human monoclonal antibody (mAb)$3090.00
GMP-EQU-C-Peptide-Ab04Anti-Equine C-Peptide human monoclonal antibody (mAb)$3090.00

Size： 1mg | 10mg | 100mg



Product Description

Cat No. GMP-EQU-C-Peptide-Ag01
Product NameEquine C-Peptide
Target/BiomarkerEquine C-Peptide
Expression platformE.coli
IsotypesRecombinant Antigen
Bioactivity validationAnti-Equine C-Peptide antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in C-Peptide level test of animal Equine/Horse with type 1 diabetes mellitus.
TagHis
Reconized/Reactive SpecicsEquine C-Peptide
Product descriptionRecombinant Equine C-Peptide protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-C-Peptide-Ab01,GMP-EQU-C-Peptide-Ab02
Target/BiomarkerEquine C-Peptide
Product NameAnti-Equine C-Peptide mouse monoclonal antibody (mAb)
Expression platformCHO
Isotypes Mouse IgG
Bioactivity validationRecombinant Equine C-Peptide antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine C-Peptide antibodies in Equine C-Peptide level test of animal Equine/Horse with type 1 diabetes mellitus.
Product descriptionAnti-Equine C-Peptide mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine C-Peptide antibodies.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-C-Peptide-Ab03,GMP-EQU-C-Peptide-Ab04
Target/BiomarkerEquine C-Peptide
Product NameAnti-Equine C-Peptide human monoclonal antibody (mAb)
Expression platformCHO
IsotypesHuman lgG1
Bioactivity validationRecombinant Equine C-Peptide antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine C-Peptide antibodies in Equine C-Peptide level test of animal Equine/Horse with type 1 diabetes mellitus.
Product descriptionAnti-Equine C-Peptide mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


    Equine C-Peptide, a remarkable peptide composed of 31 amino acids, is intricately intertwined with the physiological tapestry of horses. It emerges as a critical component of pancreatic function, serving as both a mirror and a marker of endogenous insulin production. C-Peptide is born during the proteolytic cleavage of proinsulin, a precursor to insulin. While insulin takes on the central role in regulating glucose homeostasis, Equine C-Peptide plays a parallel and equally crucial role, co-secreted alongside insulin by the pancreas.

    Equine C-Peptide follows a pulsatile release pattern into the bloodstream, a pattern that mimics the body's natural insulin secretion. This distinctive feature sets it apart from exogenously administered insulin, which delivers a continuous and uniform dose. As C-Peptide levels rise in response to elevated blood glucose levels, it serves as an invaluable indicator of the pancreas's health and its ability to produce insulin.

    Beyond its role as a mirror of insulin secretion, Equine C-Peptide plays an essential role in the diagnosis and management of metabolic disorders in horses. Conditions like equine metabolic syndrome (EMS) and insulin resistance are prevalent in the equine population and are associated with abnormal insulin responses. C-Peptide measurement offers vital insights into the source of this dysregulation, helping veterinarians differentiate between insulin production and receptor sensitivity issues.

    Equine C-Peptide is not a mere static marker; it evolves dynamically with the horse's metabolic status. This dynamic nature makes it a versatile tool in equine endocrinology. Its levels can fluctuate in response to changes in diet, exercise, and insulin sensitivity. This adaptability allows veterinarians to monitor horses over time, providing a comprehensive picture of their metabolic health.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.